CD163 and breast cancer: In accordance with the associations to adverse clinicopathological features, high densities of CD163+ immune cells associate with poor OS, breast cancer specific survival (BCSS), and/or recurrence-free survival (RFS) in patients with primary breast cancer [7–11, 13].